9 assets in Immunodeficiency Disease

Therapeutic assets addressing Immunodeficiency Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Busulfanum Immunodeficiency Disease	University of California, San Francisco	P2	BB (66)
Melphalan Immunodeficiency Disease	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	BB (66)
Fludarabine Immunodeficiency Disease	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	BB (65)
Thiotepa Immunodeficiency Disease	University of California, San Francisco	P2	BB (65)
Alemtuzumab Immunodeficiency Disease	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	B (60)
Cyclophosphamide Immunodeficiency Disease	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	B (60)
Tacrolimus Immunodeficiency Disease	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	B (57)
Levetiracetam Immunodeficiency Disease	Masonic Cancer Center, University of Minnesota	N/A	D (30)